CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

AI Briefing

• – CervoMed's neflamapimod shows promise in reversing basal forebrain degeneration in dementia with Lewy Bodies
• – New data supports potential therapeutic benefits in early-stage dementia with Lewy Bodies
• – Neflamapimod may slow disease progression with reversible effects on basal forebrain